Abstract:Abstract Central centrifugal cicatricial alopecia (CCCA) is a type of scarring alopecia, which typically starts on the crown and progresses in a centrifugal manner. It predominantly affects women of African descent and often has devastating psychosocial implications. The pathogenesis of CCCA is not fully understood and therapeutic options are limited. It has been proposed that CCCA is a fibroproliferative disorder (FPD) with persistent, low-grade inflammation resulting in end-stage fibrosis. People of African descent are at increased risk of FPDs including uterine leiomyomas (ULs), possibly due to the protective effect of profibrotic alleles against helminthic infections (Dina Y, Okoye GA, Aguh C. Association of uterine leiomyomas with central centrifugal cicatricial alopecia. JAMA Dermatol 2018; 154: 213–14). There are only eight publications to date that explore the potential link between CCCA and ULs. A retrospective cohort study found that Black women with CCCA have nearly five times increased odds of ULs, compared with Black women without CCCA (Dina et al.). Fibroproliferative genes (e.g. platelet-derived growth factor and collagen genes I and III) are upregulated in areas of scalp affected by CCCA, compared with unaffected scalp in the same patients, with an overlap in pathogenic mediators with other FPDs including atherosclerosis and hepatic fibrosis (Aguh C, Dina Y, Talbot CC Jr, Garza L. Fibroproliferative genes are preferentially expressed in central centrifugal cicatricial alopecia. J Am Acad Dermatol 2018; 79: 904–12). These findings may help identify future therapeutic targets to treat CCCA. Current approaches use anti-inflammatory medications to halt disease progression. However, unlike other scarring alopecias, patients with CCCA often have minimal visible scalp inflammation, despite worsening fibrosis and hair loss. Hence, particularly for patients who do not improve with anti-inflammatory treatments, antifibrotic agents may play a therapeutic role in the future, with medications such as losartan and statins demonstrating potential for halting CCCA progression. We conducted a retrospective cohort study among patients with CCCA presenting to our tertiary-centre hair clinic, using Black women with lichen planopilaris (LPP) as a comparator group (n = 20). We found that 80% of Black women with CCCA had reported ULs, compared with 50% of Black women with LPP. In light of this potential association, dermatologists should be encouraged to screen for symptoms of ULs, alongside other FPDs, and counsel patients regarding potential comorbidities associated with CCCA. This may allow for prompt diagnosis of life-altering comorbidities and significantly ameliorate patients’ quality of life.

BH16 Central centrifugal cicatricial alopecia and fibroproliferative disorders: exploring the association with uterine leiomyomas